ReviewBrain pathology (Zurich, Switzerland)2011
The use of global profiling in biomarker development for gliomas.
Review in Brain pathology (Zurich, Switzerland), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.BMC cancer · 2022Article
- Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value.Journal of cancer research and clinical oncology · 2020Article
- Cullin-7 (CUL7) is overexpressed in glioma cells and promotes tumorigenesis via NF-κB activation.Journal of experimental & clinical cancer research : CR · 2020Article
- DHHC protein family targets different subsets of glioma stem cells in specific niches.Journal of experimental & clinical cancer research : CR · 2019Article
- TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas.Journal of experimental & clinical cancer research : CR · 2017Article
- A novel integrated gene coexpression analysis approach reveals a prognostic three-transcription-factor signature for glioma molecular subtypes.BMC systems biology · 2016Article
- A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.Journal of neuropathology and experimental neurology · 2013Article
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.Neoplasia (New York, N.Y.) · 2013Article
- MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas.Journal of neuro-oncology · 2013Article
- Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.Neuro-oncology · 2012Article
- Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.Neuro-oncology · 2012Article
- Neuropathological diagnosis of brain tumours.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2011Article
- Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma.Oncology letters · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diffuse gliomas are a heterogeneous group of malignancies with highly variable outcomes and diagnosis is largely based on the histological appearance of the tumors. Tumor classification according to cello type and grade provides some prognostic information. However, the diversity of gliomas, within tumor type and grade categories, has made prognostic determinations based purely on clinicopathologic variables difficult. There is an increasing body of data suggesting a significant amount of molecular diversity accounts for the heterogeneity of clinical observations, such as response to treatment and time to progression. The last decade has witnessed an explosive advance in our knowledge of the molecular genetics of brain tumors, due in large part to the availability of high-throughput profiling techniques, including new sequencing methodologies as well as multidimensional profiling by the Cancer Genome Atlas project. The large amount of data generated by these efforts has enabled the identification of prognostic and predictive factors and helping to identify pathways that are driving tumor growth. Identification of biomarkers, especially when coupled to clinical trials of newer targeted therapies, will enable better patient stratification and individualization of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.